Combination Chemotherapy for Adrenocortical Cancer
Name of the Trial
Phase II Study of Combination Chemotherapy Comprising Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide and Surgery in Patients with Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (NCI-04-C-0011). See the protocol abstract at http://cancer.gov/clinicaltrials/NCI-04-C-0011.
Why Is This Trial Important?
A drug called tariquidar may make cancer cells more sensitive to chemotherapy. Tariquidar inhibits a protein called p-glycoprotein, which is found in high amounts on adrenocortical carcinoma cells. This trial combines tariquidar with chemotherapy to treat adrenocortical carcinoma. Selected patients may undergo surgery after achieving their best response to chemotherapy.
"This trial is the second of two trials to evaluate the effect of inhibiting p-glycoprotein in the treatment of adrenocortical cancer," said Dr. Menefee. "The first trial added the drug mitotane to combination chemotherapy, and with this trial we are adding tariquidar, a more potent p-glycoprotein inhibitor, to the mitotane and chemotherapy regimen.
"We believe that effective inhibition of p-glycoprotein may increase the response rate of systemic chemotherapy in adrenocortical carcinoma," Dr. Menefee explained.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.